1,474 results on '"Danesi, Romano"'
Search Results
202. Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer
203. CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone
204. KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges
205. Epileptogenesis and oncogenesis: An antineoplastic role for antiepileptic drugs in brain tumours?
206. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs
207. Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region
208. A real-world application of liquid biopsy (LB) in metastatic colorectal cancer (mCRC).
209. Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer
210. Immune Checkpoint Inhibitors and Cardiotoxicity: Reverse Translational Research by Using Real World Safety Data from the European Spontaneous Reporting System
211. Overexpression and Functional Relevance of Somatostatin Receptor-1, -2, and -5 in Endometrium and Endometriotic Lesions
212. Comment on “High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma”
213. Precision Medicine in Lymphoma by Innovative Instrumental Platforms
214. Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment
215. Circulating biomarkers of response to immunotherapy in cancer treatment
216. Corrigendum to “Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors” [Cancer Treatm. Rev. 74 (2019) 21–28]
217. METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION-RESISTANT PROSTATE CANCER
218. Pharmacogenetics in Oncology
219. Pharmacokinetic Optimisation of the Treatment of Cancer with High Dose Zidovudine
220. Cancer stem cell epigenetics and chemoresistance
221. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients
222. Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis
223. Vascular endothelial growth factor-A (VEGF-A) single nucleotide polymorphisms and endometriosis: still a controversial issue
224. Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors
225. Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction
226. Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence.
227. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer
228. AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer
229. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate
230. Vascular endothelial growth factor pharmacogenetics:: a new perspective for anti-angiogenic therapy
231. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues
232. In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma
233. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity
234. Clinical Pharmacokinetics of Irinotecan-Based Chemotherapy in Colorectal Cancer Patients
235. Importance of Preclinical Investigations of the Integration of Capecitabine into Polychemotherapy Regimens
236. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.: 291.
237. 5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice
238. Pharmacogenetics of neoplastic diseases: new trends
239. Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4′-amino-3′-hydroxy-doxorubicin
240. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529
241. Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer Is Rare
242. Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11)
243. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine
244. Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN-38
245. Biologic Basis of Ovarian Metastasis of Colorectal Cancer
246. A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy
247. Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor
248. Impact of Locoregional Approaches to Liver Metastases in Patients with Colorectal Cancer
249. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg
250. Predicting Survival with Artificial Neural Networks
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.